Literature DB >> 153576

Metabolic abnormalities of tryptophan and nicotinic acid in patients with rheumatoid arthritis.

D Labadarios, D Y McKenzie, J W Dickerson, D V Parke.   

Abstract

The mean plasma total tryptophan concentration of 13 long-standing rheumatoid arthritis patients was found to be lower than that of seven nonrheumatoid control subjects, but the plasma nicotinic acid concentration was unchanged. In the rheumatoid patients the urinary excretion of the tryptophan metabolites, kynurenine, xanthurenic acid and 3-hydroxyanthranilic acid, was increased several fold, but the excretion of N-methylnicotinamide was normal. These findings are discussed in relationship to the dietary intakes of tryptophan, nicotinic acid and pyridoxine, the effect of antirheumatoid drugs on plasma tryptophan and liver tryptophan pyrrolase, and requirement of rheumatoid patients for pyridoxine.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 153576     DOI: 10.1093/rheumatology/17.4.227

Source DB:  PubMed          Journal:  Rheumatol Rehabil        ISSN: 0300-3396


  6 in total

1.  IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.

Authors:  Lauren M F Merlo; Elizabeth Pigott; James B DuHadaway; Samantha Grabler; Richard Metz; George C Prendergast; Laura Mandik-Nayak
Journal:  J Immunol       Date:  2014-01-31       Impact factor: 5.422

2.  Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy.

Authors:  Dongdong Wang; Yasushi Saga; Hiroaki Mizukami; Naoto Sato; Hiroaki Nonaka; Hiroyuki Fujiwara; Yuji Takei; Shizuo Machida; Osamu Takikawa; Keiya Ozawa; Mitsuaki Suzuki
Journal:  Int J Oncol       Date:  2011-12-13       Impact factor: 5.650

Review 3.  IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.

Authors:  Lauren M F Merlo; Laura Mandik-Nayak
Journal:  Clin Med Insights Pathol       Date:  2016-11-21

Review 4.  Impact of IDO1 and IDO2 on the B Cell Immune Response.

Authors:  Lauren M F Merlo; Weidan Peng; Laura Mandik-Nayak
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

5.  Exploitation of the IDO Pathway in the Therapy of Rheumatoid Arthritis.

Authors:  Richard O Williams
Journal:  Int J Tryptophan Res       Date:  2013-07-21

Review 6.  Intestinal Dysbiosis and Tryptophan Metabolism in Autoimmunity.

Authors:  Josephine Brown; Brian Robusto; Laurence Morel
Journal:  Front Immunol       Date:  2020-08-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.